Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J B Porter

Showing results (21-30 of 99) with videos related to

Pageof 10
Sort By:
Blood|December 12, 2001
Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytesK H Maclean, J L Cleveland, J B Porter
Cancer Research|September 1, 1992
Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell linesK P Hoyes, R C Hider, J B Porter
European Journal of Nuclear Medicine|January 1, 1990
Inhibition of the hepatocyte uptake of radiolabelled monoclonal antibodies by chelating agentsB R Davidson, P B Boulos, J B Porter
Hemoglobin|January 1, 1988
Selection of hydroxypyridin-4-ones for the treatment of iron overload using in vitro and in vivo modelsE R Huehns, J B Porter, R C Hider
European Journal of Nuclear Medicine|October 1, 1994
Platelet labelling with indium-hydroxypyridinone and indium-hydroxypyranone complexesR D Abeysinghe, B L Ellis, J B Porter
Bailliere'S Clinical Haematology|April 1, 1989
The development of iron chelating drugsJ B Porter, E R Huehns, R C Hider
Clinical Endocrinology|September 1, 1993
Prospective study of the hypothalamic-pituitary axis in thalassaemic patients who developed secondary amenorrhoeaR Chatterjee, M Katz, T F Cox, et al.
Obstetrics and Gynecology|July 1, 1985
Oral contraceptives and nonfatal vascular diseaseJ B Porter, J R Hunter, H Jick, et al.
Advances in Experimental Medicine and Biology|January 1, 1994
Iron chelator designR C Hider, O Epemolu, S Singh, et al.
British Journal of Haematology|December 3, 1999
Determinants of iron status and bilirubin levels in congenital dyserythropoietic anaemia type IS N Wickramasinghe, S L Thein, S Srichairatanakool, et al.
Pageof 10

Showing results (21-30 of 99) with videos related to

Sort By:
Pageof 10
Blood|December 12, 2001
Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytesK H Maclean, J L Cleveland, J B Porter
Cancer Research|September 1, 1992
Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell linesK P Hoyes, R C Hider, J B Porter
European Journal of Nuclear Medicine|January 1, 1990
Inhibition of the hepatocyte uptake of radiolabelled monoclonal antibodies by chelating agentsB R Davidson, P B Boulos, J B Porter
Hemoglobin|January 1, 1988
Selection of hydroxypyridin-4-ones for the treatment of iron overload using in vitro and in vivo modelsE R Huehns, J B Porter, R C Hider
European Journal of Nuclear Medicine|October 1, 1994
Platelet labelling with indium-hydroxypyridinone and indium-hydroxypyranone complexesR D Abeysinghe, B L Ellis, J B Porter
Bailliere'S Clinical Haematology|April 1, 1989
The development of iron chelating drugsJ B Porter, E R Huehns, R C Hider
Clinical Endocrinology|September 1, 1993
Prospective study of the hypothalamic-pituitary axis in thalassaemic patients who developed secondary amenorrhoeaR Chatterjee, M Katz, T F Cox, et al.
Obstetrics and Gynecology|July 1, 1985
Oral contraceptives and nonfatal vascular diseaseJ B Porter, J R Hunter, H Jick, et al.
Advances in Experimental Medicine and Biology|January 1, 1994
Iron chelator designR C Hider, O Epemolu, S Singh, et al.
British Journal of Haematology|December 3, 1999
Determinants of iron status and bilirubin levels in congenital dyserythropoietic anaemia type IS N Wickramasinghe, S L Thein, S Srichairatanakool, et al.
Pageof 10